Spero Therapeutics Inc (NASDAQ:SPRO) shares traded -9.36% lower at $2.13 on Wall Street last session.
SPRO stock price is now 183.18% away from the 50-day moving average and 109.61% away from the 200-day moving average. The market capitalization of the company currently stands at $119.09M.
With the price target maintained at $5, Evercore ISI recently Downgraded its rating from Outperform to In-line for Spero Therapeutics Inc (NASDAQ: SPRO). On September 23, 2022, Evercore ISI Upgraded its previous ‘In-line’ rating to ‘Outperform’ on the stock increasing its target price from $2 to quote $8, while ‘Oppenheimer’ rates the stock as ‘Perform’
In other news, Keutzer Timothy, Chief Operating Officer sold 56,537 shares of the company’s stock on Feb 05 ’25. The stock was sold for $44,099 at an average price of $0.78. Upon completion of the transaction, the Chief Operating Officer now directly owns 741,439 shares in the company, valued at $1.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 05 ’25, CFO & CBO Rajavelu Esther sold 20,689 shares of the business’s stock. A total of $16,137 was realized by selling the stock at an average price of $0.78. This leaves the insider owning 724,720 shares of the company worth $1.54 million. A total of 33.16% of the company’s stock is owned by insiders.
During the past 12 months, Spero Therapeutics Inc has had a low of $0.51 and a high of $2.48. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 2.56, and a quick ratio of 2.56.
The net profit margin was -246.49% and return on equity was -107.28% for SPRO. The company reported revenue of $5.87 million for the quarter, compared to $9.27 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -36.61 percent.
